HepQuant to Present Quantification of Human and Porcine Liver Function in an Extracorporeal Liver Circuit (ELC) at the DDW 2025 Late-Breaking Plenary Session
Dr. Greg T. Everson will discuss the results of studies with 13C-cholate for liver function measurement for this application on May 3, 2025, from 2:00 to 3:00 pm at the San Diego Convention CenterHepQuant to Present at Key Liver Conferences to Highlight Applications of HepQuant DuO™ – a Quantitative Liver Health Test
Recent clinical data demonstrates how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression and evaluate response to resmetirom therapy in patients with compensated advanced chronic liver disease (cACLD). Denver, CO – March 17, 2025 – HepQuant, LLC continues to expand clinical availability of…
HepQuant Announces Additions to the Executive Leadership Team to Drive Commercialization
Kelly R. Pitts, PhD, Chief Operating Officer; Carrie Mulherin, MBA, Chief Commercial Officer; Shailesh Chavan, MD, Chief Medical Officer; Paige Nardi, MBA VP Market Access Denver, CO – June 13, 2023 – HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team….
Kelly R. Pitts, Ph.D., Appointed Chief Operating Officer
Medical Diagnostics Industry Veteran with Biotech and Biopharma Experience Will Guide Operations DENVER (Apr. 14, 2023) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced its has chosen Kelly R. Pitts, Ph.D., as its new Chief…
HepQuant Lab Moves to New Location Within Fitzsimons Innovation Community Campus
The HepQuant Lab has moved a short distance within the Fitzsimons Innovation Community Campus to Bioscience 1, located at 12635 E. Montview Blvd., Suite 175, Aurora, CO 80045. The new lab space is adjacent to our previous location where we’ve been for the past five years, according to HepQuant Chief…
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Hepion Pharma Announces First Dosing in Phase 2b Clinical Trial with HepQuant Endpoints
HepQuant Lab Meets COLA – CLIA Quality Standards
DENVER (Aug. 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that the HepQuant laboratory has achieved COLA accreditation for laboratory quality assurance. COLA is a third-party accreditation organization that ensures labs comply with federal…